Works Cited

1. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.

2. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens. 2006;24(4):621-626.

3. Mayo Clinic. Metabolic Syndrome. Available at https://www.mayoclinic.org/diseases-conditions/metabolic-syndrome/symptoms-causes/syc-20351916. Last accessed September 21, 2020.

4. Torpy JM. JAMA patient page: the metabolic syndrome. JAMA. 2006;295(7):850.

5. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28(9):2289-2304.

6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735-2752.

7. Gibbons GH1, Shurin SB, Mensah GA, Lauer MS. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. Circulation. 2013;128(15):1713-1715.

8. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143.

9. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-438.

10. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocrinol Pract. 2003;9(3):237-252.

11. Bloomgarden ZT. Definitions of the insulin resistance syndrome: the 1st World Congress on the Insulin Resistance Syndrome. Diabetes Care. 2004;27(3):824-830.

12. International Diabetes Federation. Consensus Statements. IDF Consensus Worldwide Definition of the Metabolic Syndrome. Available at https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html. Last accessed September 21, 2020.

13. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Report. 2009;13:1-5.

14. Moore JX, Chaudhary N, Akinyemiju T. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Available at https://www.cdc.gov/pcd/issues/2017/16_0287.htm. Last accessed September 21, 2020.

15. Centers for Disease Control and Prevention. Childhood Obesity Facts: Prevalence of Childhood Obesity in the United States. Available at https://www.cdc.gov/obesity/data/childhood.html. Last accessed September 21, 2020.

16. Centers for Disease Control and Prevention. Adult Obesity Facts. Available at https://www.cdc.gov/obesity/data/adult.html. Last accessed September 21, 2020.

17. Curtis LH, Hammill BG, Bethel MA, Anstrom KJ, Gottdiener JS, Schulman KA. Costs of the metabolic syndrome in elderly individuals: findings from the Cardiovascular Health Study. Diabetes Care. 2007;30(10):2553-2558.

18. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;43(9):1-12.

19. Centers for Disease Control and Prevention. National Diabetes Statistic Report, 2020. Available at https://www.cdc.gov/diabetes/data/statistics-report/index.html. Last accessed September 21, 2020.

20. Lopez-Candales A. Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. J Med. 2001;32(5-6):283-300.

21. Wang SS. Metabolic Syndrome. Available at https://emedicine.medscape.com/article/165124-overview. Last accessed September 21, 2020.

22. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54(1):24-38.

23. Singh U, Jialal I. Oxidative stress and atherosclerosis. Pathophysiology. 2006;13(3):129-142.

24. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15(4):6184-6223.

25. Taber's Online. Available at https://www.tabers.com/tabersonline. Last accessed September 21, 2020.

26. St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care. 2004;27(9):2222-2228.

27. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81(3):555-563.

28. Bray GA, Jablonski KA, Fujimoto WY, et al. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr. 2008;87(5):1212-1218.

29. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002;25(1): 134-147.

30. Mayo Clinic. Hyperinsulinemia: Is It Diabetes? Available at https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/expert-answers/hyperinsulinemia/faq-20058488?p=1. Last accessed September 21, 2020.

31. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101(9):975-980.

32. Abdul-Ghani MA, Williams K, DeFronzo R, Stern M. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care. 2006;29(7):1613-1618.

33. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30(1):8-13.

34. Benjamin EJ, Muntner P, Alonso, et al, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528.

35. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation. 2003;108(13):1546-1551.

36. Sundstrom J, Vallhagen E, Riserus U, et al. Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care. 2006;29(7):1673-1674.

37. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93(2):136-141.

38. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210-1214.

39. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709-2716.

40. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414-419.

41. McNeill AM, Katz R, Girman CJ, et al. Metabolic syndrome and cardiovascular disease in older people: the Cardiovascular Health Study. J Am Geriatr Soc. 2006;54(9):1317-1324.

42. Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med. 2008;168(9):969-978.

43. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005;28(2):385-390.

44. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs. Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22):2644-2650.

45. Wannamethee SG. The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. Int J Obes (Lond). 2008;32(Suppl 2)S25-S29.

46. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769-1778.

47. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10): 812-819.

48. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403-414.

49. Levesque J, Lamarche B. The metabolic syndrome: definitions, prevalence and management. J Nutrigenet Nutrigenomics. 2008;1(3):100-108.

50. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113-1132.

51. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84(5):1513-1517.

52. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143(10):722-728.

53. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167-174.

54. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16(7):2134-2140.

55. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115.

56. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120(5):442-447.

57. Goldbacher EM, Matthews KA. Are psychological characteristics related to risk of the metabolic syndrome? A review of the literature. Ann Behav Med. 2007;34(3):240-252.

58. Sardinha A, Nardi AE. The role of anxiety in metabolic syndrome. Expert Rev Endocrinol Metab. 2012;7(1):63-71.

59. National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Adult Treatment Panel III final report. Circulation. 2002;106(25):3143-3421.

60. Grundy SM, Hansen B, Smith SC, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551-556.

61. Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and TsDM in patients at metabolic risk: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(9):3939-3985.

62. U.S. Preventive Services Task Force. Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Risk Factors: U.S. Preventive Services Task Force Recommendation Statement. Washington, DC: U.S. Preventive Services Task Force; 2017.

63. Patnode CD, Evans CV, Senger CA, Redmond N, Lin JS. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: updated evidence report and systematic review for the U.S. Preventive Services Task Force. JAMA. 2017;318(2):175-193.

64. Wright JD, Wang C-Y. Trends in Intake of Energy and Macronutrients in Adults From 1999–2000 Through 2007–2008. NCHS Data Brief, No. 49. Hyattsville, MD: National Center for Health Statistics; 2010.

65. Kant AK, Graubard BI. Secular trends in patterns of self-reported food consumption of adult Americans: NHANES 1971–1975 to NHANES 1999–2002. Am J Clin Nutr. 2006;84(5):1215-1223.

66. Centers for Disease Control and Prevention. Americans Slightly Taller, Much Heavier than Four Decades Ago. Available athttps://www.cdc.gov/nchs/pressroom/04news/americans.htm. Last accessed September 21, 2020.

67. National Institute of Diabetes and Digestive and Kidney Diseases. Overweight and Obesity Statistics. Available at https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity#econ. Last accessed September 21, 2020.

68. Kant AK, Graubard BI. 40-year trends in meal and snack eating behaviors of American adults. J Acad Nutr Diet. 2015;115(1):50-63.

69. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63;25.

70. Hannum SM, Carson L, Evans EM, et al. Use of portion-controlled entrees enhances weight loss in women. Obes Res. 2004;12(3):538-546.

71. Hannum SM, Carson LA, Evans EM, et al. Use of packaged entrees as part of a weight-loss diet in overweight men: an 8-week randomized clinical trial. Diabetes Obes Metab. 2006;8(2):146-155.

72. U.S. Department of Agriculture. USDA ChooseMyPlate.gov. Available at https://www.choosemyplate.gov. Last accessed September 21, 2020.

73. Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: National Academies Press; 2005.

74. Schwingshackl L, Hoffmann G. Long-term effects of low-fat diets either low or high in protein on cardiovascular and metabolic risk factors: a systematic review and meta-analysis. Nutr J. 2013;12:48.

75. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43-53.

76. Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA. 2007;297(9):969-977.

77. Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004;140(10):778-785.

78. U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2015–2020, 8th ed. Available at https://health.gov/dietaryguidelines/2015/resources/2015-2020_Dietary_Guidelines.pdf. Last accessed September 21, 2020.

79. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd ed. Washington, DC: U.S. Department of Health and Human Services; 2018.

80. U.S. Department of Agriculture. USDA ChooseMyPlate.gov. Available at https://www.choosemyplate.gov. Last accessed September 21, 2020.

81. Pucci G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: a review of the literature. PharmacolRes. 2017;120:34-42.

82. Myers J, McAuley P, Lavie C, Despres JP, Arena R, Kokkinos P. Physical activity and cardiorespiratory fitness as major markers of cardiovascular risk: their independent and interwoven importance to health status. Prog Cardiovasc Dis. 2015;57:306-314.

83. US Department of Health and Human Services Physical Activity: Facts and Statistics. Available at https://www.hhs.gov/fitness/resource-center/facts-and-statistics/index.html. Last accessed September 21, 2020.

84. Chau J, Chey T, Burks-Young S, Engelen L, Bauman A. Trends in prevalence of leisure time physical activity and inactivity: results from Australian National Health Surveys 1989 to 2011. Aust NZJ Pub Health. 2017;41:617-624.

85. Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;380:247-257.

86. Duncan G.E. Exercise, fitness, and cardiovascular disease risk in type 2 diabetes and the metabolic syndrome. Curr Diab Rep. 2006;6:29-35.

87. Church T. Exercise in obesity, metabolic syndrome, and diabetes. Prog Cardiovasc Dis. 2011;53:412-418.

88. National Center for Chronic Disease Prevention and Health Promotion. Physical Activity and Health: A Report of the Surgeon General. Available at https://www.cdc.gov/nccdphp/sgr/index.htm. Last accessed September 21, 2020.

89. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39(8):1423-1434.

90. Wessel TR, Arant CB, Olson MB, et al. Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA. 2004;292(10):1179-1187.

91. Carnethon MR, Gidding SS, Nehgme R, Sidney S, Jacobs DR Jr, Liu K. Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors. JAMA. 2003;290(23):3092-3100.

92. Church TS, Cheng YJ, Earnest CP, et al. Exercise capacity and body composition as predictors of mortality among men with diabetes. Diabetes Care. 2004;27(1):83-88.

93. Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN. Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness. Diabetes Care. 2005;28(2):391-397.

94. Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med. 2004;164(10):1092-1097.

95. Farrell SW, Cheng YJ, Blair SN. Prevalence of the metabolic syndrome across cardiorespiratory fitness levels in women. Obes Res. 2004;12(5):824-830.

96. Hassinen M, Lakka TA, Savonen K, et al. Cardiorespiratory fitness as a feature of metabolic syndrome in older men and women: the Dose-Responses to Exercise Training study (DR's EXTRA). Diabetes Care. 2008;31(6):1242-1247.

97. Hassinen M, Lakka TA, Hakola L, et al. Cardiorespiratory fitness and metabolic syndrome in older men and women: the dose responses to Exercise Training (DR's EXTRA) study. Diabetes Care. 2010;33(7):1655-1657.

98. Brouwer BG, Visseren FL, van der Graaf Y. The effect of leisure-time physical activity on the presence of metabolic syndrome in patients with manifest arterial disease: the SMART study. Am Heart J. 2007;154(6):1146-1152.

99. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation. 2005;112(4):505-512.

100. Case CC, Jones PH, Nelson K, O'Brian Smith E, Ballantyne CM. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002;4(6):407-414.

101. Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis. 2016;5.

102. Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27(8):2067-2073.

103. Fitch A, Everling L, Fox C, et al. Prevention and Management of Obesity for Adults. Bloomington, MN: Institute for Clinical Systems Improvement; 2013.

104. Mayo Clinic. Obesity: Diagnosis and Treatment. Available at https://www.mayoclinic.org/diseases-conditions/obesity/diagnosis-treatment/drc-20375749. Last accessed September 21, 2020.

105. Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag. 2007;3(6):817-821.

106. LexiComp Online. Available at https://online.lexi.com/lco/action/login. Last accessed September 21, 2020.

107. Shekelle PG, Morton SC, Maglione MA, et al. Evidence Report/Technology Assessment Number 103: Pharmacological and Surgical Treatment of Obesity. Available at https://archive.ahrq.gov/downloads/pub/evidence/pdf/obespharm/obespharm.pdf. Last accessed September 21, 2020.

108. U.S. Food and Drug Administration. Orlistat (Marketed as Alli and Xenical) Information. Available at https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm180076.htm. Last accessed September 21, 2020.

109. U.S. Food and Drug Administration. FDA Briefing Document: NDA 22529 Lorcaserin Hydrochloride Tablets, 10 mg. Available at https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/orlistat-marketed-alli-and-xenical-information. Last accessed September 21, 2020.

110. U.S. Food and Drug Administration. FDA Requests the Withdrawal of the Weight-Loss Drug Belviq, Belviq XR (Lorcaserin) From the Market. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market. Last accessed September 21, 2020.

111. U.S. Food and Drug Administration. [Archive]. FDA Approves Weight-Management Drug Qsymia. Available at https://wayback.archive-it.org/7993/20170112130442/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm. Last accessed September 21, 2020.

112. Drugs.Com. FDA Approves Contrave. Available at https://www.drugs.com/newdrugs/fda-approves-contrave-bupropion-naltrexone-weight-management-4081.html. Last accessed September 12, 2020.

113. Tucker ME. FDA Approves Liraglutide (Saxenda) for Weight Loss. Available at https://www.medscape.com/viewarticle/837147. Last accessed September 21, 2020.

114. U.S. Food and Drug Administration. Abbott Laboratories Agrees to Withdraw its Obesity Drug Meridia. Available at https://www.fiercepharma.com/pharma/abbott-laboratories-agrees-to-withdraw-its-obesity-drug-meridia. Last accessed September 21, 2020.

115. Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;(8):CD003641.

116. Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond). 2013;37(6):889-891.

117. Centers for Disease Control and Prevention. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017–2018. Available at https://www.cdc.gov/nchs/products/databriefs/db360.htm. Last accessed September 21, 2020.

118. Brown A. In U.S., Obesity Rate Stable in 2012. Available at https://news.gallup.com/poll/160061/obesity-rate-stable-2012.aspx. Last accessed September 21, 2020.

119. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-1737.

120. Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142(7):547-559.

121. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934.

122. Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA. 2013;309(21):2250-2261.

123. Sjöstrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.N Engl J Med. 2004;351(26):2683-2693.

124. Sjöstrom L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond). 2008;32(Suppl 7):S93-S97.

125. Batsis JA, Romero-Corral A, Collazo-Clavell ML, Sarr MG, Somers VK, Lopez-Jimenez F. Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc. 2008;83(8):897-907.

126. Lee WJ, Huang MT, Wang W, Lin CM, Chen TC, Lai IR. Effects of obesity surgery on the metabolic syndrome. Arch Surg. 2004;139(10):1088-1092.

127. Cerci M, Bellini MI, Russo F, et al. Bariatric surgery in moderately obese patients: a prospective study. Gastroenterol Res Pract. 2013;276183.

128. Kafali ME, Sahin M, Ece I, et al. The effects of bariatric surgical procedures on the improvement of metabolic syndrome in morbidly obese patients: comparison of laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass. Turk J Surg. 2017;33(3):142-146.

129. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of pre-diabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933-946.

130. The Task Force for diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323.

131. Santaguida PL, Balion C, Hunt D, et al. Evidence Report/Technology Assessment Number 128: Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose. Available at https://archive.ahrq.gov/clinic/epcsums/impglusum2.htm. Last accessed September 21, 2020.

132. Madani NH, Ismail-Beigi F, Poustchi H, et al. Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study. BMC Cardiovascular Disorders. 2020;20(113):1-11.

133. Centers for Disease Control and Prevention. U.S. Department of Health and Human Services. National Diabetes Statistics Report, 2020: Estimates of Diabetes and Its Burden in the United States. Available at https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.Pdf. Last accessed September 21, 2020.

134. Ohlson LO, Larrson B, Bjorntorp P, et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus: thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia. 1988;31(11):798-805.

135. Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. Am J Clin Nutr. 2006;84(3): 483-489.

136. Qiao Q, Nyamdorj R. Is the association of type II diabetes with waist circumference or waist-to-hip ratio stronger than that with body mass index? Eur J Clin Nutr. 2010;64(1):30-34.

137. Stokes A, Preston SH. The contribution of rising adiposity to the increasing prevalence of diabetes in the United States. Prev Med. 2017;101:91-95.

138. Goff DC Jr, Gerstein HC, Ginsberg HN, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12a):4i-20i.

139. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.

140. American Diabetes Association. Standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Suppl 1):S1-S224.

141. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015;21(Suppl 1):1-87.

142. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611-619.

143. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350.

144. Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368(9548):1673-1679.

145. Lindström J, Peltonen M, Eriksson JG, et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013;56(2):284-293.

146. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783-1789.

147. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.Am J Med. 2008;121(2):149-157.

148. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51(9):2796-2803.

149. U.S. Food and Drug Administration. Rezulin (Troglitazone). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20720s12lbl.pdf. Last accessed September 21, 2020.

150. U.S. Department of Health and Human Services. Rezulin to be Withdrawn from the Market. Available at https://www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a_tab6c.htm. Last accessed September 21, 2020.

151. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55(2):517-522.

152. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096-1105.

153. U.S. Food and Drug Administration. Avandia (Rosiglitazone) Labels Now Contain Updated Information about Cardiovascular Risks and Use in Certain Patients. Available at https://www.fda.gov/Drugs/DrugSafety/ucm241411.htm. Last accessed September 21, 2020.

154. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Eliminates the Risk Evaluation and Mitigation Strategy (REMS) for Rosiglitazone-Containing Diabetes Medicines. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-eliminates-risk-evaluation-and-mitigation-strategy-rems. Last accessed September 21, 2020.

155. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Eliminates the Risk Evaluation and Mitigation Strategy (REMS) for Rosiglitazone-Containing Diabetes Medicines. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-eliminates-risk-evaluation-and-mitigation-strategy-rems. Last accessed September 21, 2020.

156. U.S. Food and Drug Administration. Update to Ongoing Safety Review of Actos (Pioglitazone) and Increased Risk of Bladder Cancer. Available at https://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Last accessed September 21, 2020.

157. U.S. Food and Drug Administration. FDA Drug Safety Communication: Updated FDA Review Concludes That Use of Type 2 Diabetes Medicine Pioglitazone May Be Linked to an Increased Risk of Bladder Cancer. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-fda-review-concludes-use-type-2-diabetes-medicine-pioglitazone. Last accessed September 21, 2020.

158. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359(9323):2072-2077.

159. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia. 2004;47(6):969-975.

160. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393.

161. American Diabetes Association. Prevention or delay of type 2 diabetes. Diabetes Care. 2015;38(Suppl 1):S31-S32.

162. Endocrine Today. Lifestyle Intervention, Metformin Eased Financial Burden of Diabetes in DPP. Available at https://www.healio.com/news/endocrinology/20120325/lifestyle-intervention-metformin-eased-financial-burden-of-diabetes-in-dpp. Last accessed September 21, 2020.

163. MedlinePlus. Cholesterol Testing and Results. Available at https://medlineplus.gov/ency/patientinstructions/000386.htm. Last accessed September 21, 2020.

164. Management of Dyslipidemia Working Group. VA/DoD Clinical Practice Guideline for the Management of Dyslipidemia for Cardiovascular Risk Reduction. Washington, DC: Department of Veterans Affairs, Department of Defense; 2014.

165. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.

166. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;e1-e120.

167. American Heart Association. HDL (Good), LDL (Bad) Cholesterol and Triglycerides. Available at https://www.heart.org/en/health-topics/cholesterol/hdl-good-ldl-bad-cholesterol-and-triglycerides. Last accessed September 21, 2020.

168. Moon YS, Kashyap ML. Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacotherapy. 2004;24(12):1692-1713.

169. Institute for Clinical Systems Improvement. Lipid Management in Adults, 14th ed. Bloomington, MN: Institute for Clinical Systems Improvement; 2017.

170. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998;339(1):12-20.

171. Davidson MH, Maki KC, Karp SK, Ingram KA. Management of hypercholesterolemia in postmenopausal women. Drugs Aging. 2002;19(3):169-178.

172. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008;14(8 Suppl):S3-S28.

173. Jaywant SV, Singh AK, Prabhu MS, Ranjan R. Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: the dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study. Indian Heart J. 2016;68(5):646-654.

174. Tenebaum A, Fisman EZ. "If it ain't broke, don't fix it:" a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol. 2010;15:9-24.

175. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012;11:125.

176. Rosenblit PD. Do persons with diabetes benefit from combination statin and fibrate therapy? Curr Cardiol Rep. 2012;14(1):112-124.

177. Federal Register. AbbVie Inc. et al.; Withdrawal of Approval of Indications Related to the Coadministration With Statins in Applications for Niacin Extended-Release Tablets and Fenofibric Acid Delayed-Release Capsules. Available at https://www.federalregister.gov/documents/2016/04/18/2016-08887/abbvie-inc-et-al-withdrawal-of-approval-of-indications-related-to-the-coadministration-with-statins. Last accessed September 21, 2020.

178. Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2:370-380.

179. Ding Y, Li YW, Wen AD. Effect of niacin on lipids and glucose in patients with type 2 diabetes: a meta-analysis of randomized, controlled clinical trials. Clin Nutrition. 2015;34(5):838-844.

180. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000;284(10):1263-1270.

181. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162(14):1568-1576.

182. Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol: the HDL Atherosclerosis Treatment Study. Am J Cardiol. 2004;93(3):307-312.

183. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension Prevalence and Control Among Adults: United States, 2015NCHS Data Brief, No. 289. Hyattsville, MD: National Center for Health Statistics; 2017.

184. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.

185. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289(19):2560-2571.

186. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.

187. Watkins LL, Sherwood A, Feinglos M, et al. Effects of exercise and weight loss on cardiac risk factors associated with syndrome X. Arch Intern Med. 2003;163(16):1889-1895.

188. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials.Ann Intern Med. 2002;136(7):493-503.

189. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24(2):215-233.

190. National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Blood Pressure. Available at https://www.nhlbi.nih.gov/files/docs/public/heart/hbp_low.pdf. Last accessed September 21, 2020.

191. Sacks FM, Svetkey LP, Vollmer VM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3-10.

192. Karanja N, Erlinger TP, Pao-Hwa L, Miller ER 3rd, Bray GA. The DASH diet for high blood pressure: from clinical trial to dinner table. Cleve Clin J Med. 2004;71(9):745-753.

193. Craddick SR, Elmer PJ, Obarzanek E, Vollmer WM, Svetkey LP, Swain MC. The DASH diet and blood pressure. Curr Atheroscler Rep. 2003;5(6):484-491.

194. Streppel MT, Arends LR, van 't Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med. 2005;165(2):150-156.

195. Blumenthal JA, Babyak MA, Hinderliter A, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170(2):126-135.

196. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941-1951.

197. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006;17(4 Suppl 2):S90-S97.

198. Aggarwal N, Kare PK, Varshney P, et al. Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients. World J Diabetes. 2017;8(3):112-119.

199. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004-1010.

200. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003.

201. Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5:CD003824.

202. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program: SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7):741-751.

Evidence-Based Practice Recommendations Citations

1. U.S. Preventive Services Task Force. Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults with Cardiovascular Risk Factors: Behavioral Counseling. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/healthy-diet-and-physical-activity-counseling-adults-with-high-risk-of-cvd. Last accessed October 13, 2020.

2. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans. 2nd ed. Washington, DC: U.S. Department of Health and Human Services; 2018. Available at https://health.gov/paguidelines/second-edition/pdf/Physical_Activity_Guidelines_2nd_edition.pdf. Last accessed October 13, 2020.

3. Diagnosis and Management of Hypertension Working Group. Diagnosis and Management of Hypertension (HTN) in Primary Care. Washington, DC: Department of Veterans Affairs, Department of Defense; 2020. Available at https://www.healthquality.va.gov/guidelines/CD/htn. Last accessed October 13, 2020.


Copyright © 2020 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.